Exploring treatment response in AS versus non-radiographic axSpA


Ankylosing spondylitis (AS) is the severe, end stage phenotype of axial spondyloarthritis (axSpA), which also comprises an earlier, undifferentiated state, referred to as non-radiographic axSpA. Although biologics have revolutionized the management of patients with axSpA, there are limited data evaluating the treatment response between subjects with AS and nr-axSpA. 
The team's aid is to explore the BSR registry for AS with the main hypothesis being if treatment response to biologic agents in real life at 1 year follow-up can be predicted by being classified as ankylosing spondylitis or non-radiographic spondyloarthritis.

Facts and figures

Project lead
X Michelena Vegas
Hospital Universitari de Bellvitge
FOREUM research grant: €50'000
2019 - 2020

Meet the team

X Michelena Vegas
Hospital Universitari de Bellvitge
JM Nolla Solé
Hospital Universitari de Bellvitge
H Marzo-Ortega
University of Leeds


Primary objective: To explore the differences between AS and nr-axSpA populations in the BSRBR-AS register.
Secondary objective: To determine whether radiographic status predicts response to biologic therapy measured by ASDAS, considering the axSpA population treated with biologics.